A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.

Daniel BoiarskyAlok K TewariDoga C GulhanZiad BakounyGuruprasad AnandaHunter SavignanoGitanjali LakshminarayananHeather M McClureRebecca SilverToni K ChoueiriMary-Ellen TaplinPeter J ParkJacob E Berchuck

Published in: The Prostate (2024)

SigMA-predicted HRD may better identify patients likely to benefit from olaparib as compared to the current FDA label. Larger studies are needed for further validation.

Keyphrases

dna repair
dna damage
end stage renal disease
ejection fraction
newly diagnosed
squamous cell carcinoma
small cell lung cancer
chronic kidney disease
prognostic factors
oxidative stress
patient reported outcomes
patient reported